Day: July 29, 2021

Orlando, Florida, July 29, 2021 (GLOBE NEWSWIRE) — IZEA Worldwide, Inc. (NASDAQ: IZEA), operator of IZEAx®, the premier online marketplace connecting brands and publishers with influential content creators, today announced that its conference call to review and discuss first quarter financial results will begin at 5:00 p.m. Eastern Daylight Time on August 12, 2021. IZEA’s Chairman and CEO Ted Murphy, CFO Peter Biere, and COO Ryan Schram, will host the call, followed by a question and answer period. Date: Thursday, August 12, 2021 Time: 5:00 p.m. Eastern Daylight TimeToll-free dial-in number: 1-800-786-6705International dial-in number: 1-212-231-2931 Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization. A replay of the call will be available after...

Data show dose–dependent suppression of immune-suppressive agents GEN-1 stimulates the immune system through the production of CD4 and CD8 cells Chemotherapy Response Score tripled in the two highest doses of GEN-1 and is double that of chemotherapy alone LAWRENCEVILLE, N.J., July 29, 2021 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the publication of data from its Phase 1b OVATION 1 Study with GEN-1 in combination with neoadjuvant chemotherapy (NACT) in patients with advanced ovarian cancer in Clinical Cancer Research, a journal of the American Association for Cancer Research. The study, authored by Premel H. Thaker, et al. is titled “GEN-1 in Combination with Neoadjuvant Chemotherapy for Patients with Advanced...

Chatsworth, CA, July 29, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Cavitation Technologies, Inc. (OTCQB: CVAT; Berlin: WTC) today announced a significant expansion of its global patent portfolio, demonstrating its ongoing commitment to innovation and leadership in cavitation systems and processes. “From the beginning, we recognized the importance of developing and then protecting our technology,” said Roman Gordon, Global Technology Manager. “As a pioneer in cavitation, we know via our priority dates that we were and are ahead of the competition. To have our creativity recognized by patent offices around the globe (United States, Canada, Europe, Argentina, Brazil, Mexico, and others) is a source of pride for the entire CTI team and should be very comforting to our Customers, Partners and Investors.” Cavitation Technologies,...

Simufilam Significantly Improved Biomarkers in Alzheimer’s Patients Treated for 6 MonthsRobust Improvements Seen in All Measured Biomarkers of Disease, Neurodegeneration and Neuroinflammation (p< 0.00001)Biomarker Improvements Track with Cognitive ImprovementsOral Presentation at AAIC TodayAUSTIN, Texas, July 29, 2021 (GLOBE NEWSWIRE) — Cassava Sciences, Inc. (Nasdaq: SAVA) today announced positive biomarker data from an open-label study of simufilam, the Company’s investigational drug for the treatment of Alzheimer’s disease. In a clinical study funded by the National Institutes of Health (NIH), simufilam significantly improved all measured biomarkers in patients with Alzheimer’s disease following 6 months of open-label treatment. Biomarkers are objective biological data. There are no placebo effects. Cerebrospinal fluid...

Simufilam Significantly Improves Cognition in Patients with Alzheimer’s in Interim Analysis of Open-label Study at 9 MonthsCognition Improved 3.0 Points on ADAS-Cog at 9 Months (p

Today, Rolf Sveinung Heggen, General Counsel, exercised 15,000 stock options at a strike price of NOK 91.56 per share, and in separate transactions purchased 15,000 shares and sold 13,500 shares. The shares are drawn from Borregaard’s holdings of treasury shares. Please, see attached notifications for persons discharging managerial responsibilities in Borregaard in accordance with Regulation EU 596/2014 (MAR) article 19. After the transactions, Rolf Sveinung Heggen and related parties own 24,310 shares and holds 53,000 stock options in Borregaard. The total number of outstanding Borregaard stock options following this transaction is 1,329,143. Borregaard owns 430,029 treasury shares, representing 0.43% of the total number of shares outstanding. Borregaard ASASarpsborg, 29 July 2021 Contact:Lotte Kvinlaug, Investor Relations Officer, +...

Dallas, TX, July 29, 2021 (GLOBE NEWSWIRE) — Alternet Systems, Inc. (OTC Pink: ALYI) (“ALYI”) today published a report from the CEO, Randell Torno, on the company’s electric motorcycle pilot launched earlier this month. The report is included in its entirety below: CEO Electric Motorcycle Pilot Report As this pilot report update is being published, I should be in the air on the first leg of my latest journey to Nairobi where we are building the foundation of our global electric vehicle ecosystem.  One of the purposes of my trip is to prepare our partners for a media campaign surrounding our latest business developments. To advance our overall business, we recognize the importance of demonstrating our progress through narrative, pictures, and videos.  The prevailing world of YouTube, Twitter, Reddit and the like is both empowering...

Gig Harbor, Washington, July 29, 2021 (GLOBE NEWSWIRE) — Harbor Custom Development, Inc. (“Harbor,” “Harbor Custom Homes®,” or the “Company”), (NASDAQ:HCDI), an innovative and market leading real estate company involved in all aspects of the land development cycle, today announced that it has entered into term sheets with US Capital Global for credit facilities totaling $158,400,000 to provide construction financing on three Western Washington condominium projects and one in Southwest Florida.  “We are delighted to enter into a relationship with US Capital Global which has the ability to provide us construction financing on a national scale.  US Capital Global fills a key role by offering a one stop shop for our land development and vertical construction financing needs,” stated Sterling Griffin, President and CEO of Harbor Custom...

CHARLOTTESVILLE, Va., July 29, 2021 (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that an op-ed from Adial’s CEO, William Stilley, has been featured on Nasdaq.com. The op-ed, titled “Why We Need More ‘Moonshot’ Businesses” is available at: https://www.nasdaq.com/articles/why-we-need-more-moonshot-businesses-2021-07-28 In the article, Mr. Stilley discusses the need to tackle monumental challenges facing our nation in order to build stronger businesses, stronger industries and a more resilient economy. Among the topics discussed, Mr. Stilley highlights the need to address the devastating impacts of Alcohol Use Disorder, which afflicts more than 30 million people  in the United States alone. The...